Using a transplantable, immune competent, orthotopic murine model of UPS that recapitulates the lymphocyte poor TIME of most STS, we sought to determine if STING immunotherapy could dismantle the immunosuppressive features of this model and promote immunogenic tumor eradication. The gene discussed is STING1; the disease is telomere syndrome.